15 February 2017
Vectura Group plc: Notice of Preliminary Results
Chippenham, UK: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, plans to announce its Preliminary Results for the nine month period ended 31 December 2016 on Tuesday 21 March 2017.
James Ward-Lilley, Chief Executive Officer, and Andrew Derodra, Chief Financial Officer,will host a briefing for analysts at 9.30am on the morning of results in the Guildhall Room, 85 Gresham Street, London, EC2R 7HE.
A live webcast of the meeting, with the presentation slides, will be made available on Vectura’s website: http://www.vectura.com/investors/presentations-webcasts/.
Vectura Group plc
Andrew Derodra – Chief Financial Officer
Fleur Wood – Director Communications
Elizabeth Knowles – Director Investor Relations and Analysis
+44 (0)1249 667700
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson
+44 (0)20 3709 5700
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and “smart” nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.
Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.